- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Litigation Support Services
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
-
May 10, 2021Robins Kaplan Appointed Interim Lead Counsel in Antitrust Class Action Against Martin Shkreli and His Former Companies
-
May 7, 2021Robins Kaplan Attorneys Nominated for Antitrust Writing Awards 2021
-
April 26, 2021Amy Churan Named to L.A. Business Journal’s “Women of Influence” List
-
May 17, 2021Practice Pointers for Virtual Hearings
-
May 19, 2021Minnesota IP Law Association (MIPLA) Virtual Stampede
-
May 5, 12, and 19, 2021Second Annual AI Legal Summit
-
May 5, 2021Bio-Rad Ruling Highlights IP Assignment Clause Limits
-
May 3, 2021Maintain A Foothold
-
April 20, 2021Copyright Concerns For NFT Buyers, Sellers In Music Industry
-
May 13, 2021Financial Daily Dose 5.13.2021 | Top Story: Stocks Continue Slide as CPI Shows Price Jump in U.S.
-
May 12, 2021Financial Daily Dose 5.12.2021 | Top Story: Fed Stands Pat on Strategy Despite Inflation Worries Roiling Markets
-
May 11, 2021Financial Daily Dose 5.11.2021 | Top Story: FBI Identifies Hackers Behind Pipeline Attack
Find additional firm contact information for press inquiries.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Judge Rules Collegium Pharmaceutical Inc. Does Not Infringe Two OxyContin Patents
October 1, 2018
A Massachusetts federal judge recently ruled that Robins Kaplan client Collegium Pharmaceutical Inc. did not infringe upon two of Purdue Pharma LP’s OxyContin-related patents. The ruling represents a significant victory for Collegium and its two-year-old drug, Xtampza XR.
Law360 covered the ruling in a recent article:
Xtampza Not Infringing 2 OxyContin Patents, Judge Says
All Content © 2018, Portfolio Media, Inc.
Related Publications
May 5, 2021
Bio-Rad Ruling Highlights IP Assignment Clause Limits
Bryan J. Vogel, Derrick J. Carman - Law360
April 20, 2021
Copyright Concerns For NFT Buyers, Sellers In Music Industry
Carly Kessler - Law360
March 26, 2021
Trends In Video Game Company Quests To Arbitrate Cases
Matthew Woods, Austin Miller - Law360
March 24, 2021
NFTs Are Reshaping Artists’ IP Rights
Carly Kessler - Bloomberg Law
February 3, 2021
Navigating Software License Disputes in the Continuing Work-From-Home World
Bryan Mechell, Ellen Levish
Related News
April 21, 2021
March 1, 2021
September 15, 2020
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.